Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination

Daniel F Hoft; Kathleen Lottenbach; Johannes B Goll; Heather Hill; Patricia L Winokur; Shital M Patel; Rebecca C Brady; Wilbur H Chen; Kathryn Edwards; C Buddy Creech; Sharon E Frey; Tamara P Blevins; Rachelle Salomon; Robert B Belshe

doi:10.1093/infdis/jiw310

Back

Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination

Journal article

Open access

Peer reviewed

Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination

Daniel F Hoft, Kathleen Lottenbach, Johannes B Goll, Heather Hill, Patricia L Winokur, Shital M Patel, Rebecca C Brady, Wilbur H Chen, Kathryn Edwards, C Buddy Creech, …

The Journal of infectious diseases, Vol.214(7), pp.1020-1029

10/01/2016

DOI: 10.1093/infdis/jiw310

PMCID: PMC5021235

PMID: 27443611

Files and links (1)

url

https://doi.org/10.1093/infdis/jiw310View

Published (Version of record) Open Access

Abstract

Influenza A(H5N1) virus and other avian influenza virus strains represent major pandemic threats. Like all influenza A virus strains, A(H5N1) viruses evolve rapidly. Innovative immunization strategies are needed to induce cross-protective immunity. Subjects primed with clade 1 H5 antigen, with or without adjuvant, and H5-naive individuals were boosted with clade 2 H5 antigen. The impact of priming on T cells capable of both proliferation and cytokine production after antigen restimulation was assessed. Subjects previously vaccinated with clade 1 H5 antigen developed significantly enhanced clade 2 H5 cross-reactive T cell responses detectable 6 months after vaccination with clade 2 H5 antigen. Priming dose (15 µg vs 45 or 90 µg) had no effect on magnitude of heterotypic H5 T cell responses. In contrast, age at priming negatively modulated both the magnitude and duration of heterotypic H5 T cell responses. Elderly subjects developed significantly less heterotypic H5 T cell boosting, predominantly for T cells capable of cytokine production. Adjuvant had a positive albeit weaker effect than age. The magnitude of CD4(+) interferon-γ producing T cells correlated with H5 antibody responses. H5 heterotypic priming prior to onset of an A(H5N1) pandemic may increase magnitude and duration of immunity against a newly drifted pandemic H5 virus.

Influenza Vaccines - administration & dosage

Cell Proliferation

Double-Blind Method

Hemagglutinin Glycoproteins, Influenza Virus - administration & dosage

Humans

Middle Aged

Cytokines - secretion

Male

Hemagglutinin Glycoproteins, Influenza Virus - immunology

Immunity, Heterologous

Young Adult

Influenza Vaccines - immunology

Vaccination - methods

Aged, 80 and over

Adult

Female

T-Lymphocytes - immunology

Aged

Influenza, Human - prevention & control

Details

Title: Subtitle: Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination
Creators: Daniel F Hoft - Department of Internal Medicine, Saint Louis University, Missouri
Kathleen Lottenbach - Department of Internal Medicine, Saint Louis University, Missouri
Johannes B Goll - Emmes Corporation, Rockville
Heather Hill - Emmes Corporation, Rockville
Patricia L Winokur - Department of Internal Medicine, University of Iowa and Iowa City VA Healthcare System
Shital M Patel - Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas
Rebecca C Brady - Gamble Program for Clinical Studies, Cincinnati Children's Hospital, Ohio
Wilbur H Chen - Center for Vaccine Development, University of Maryland School of Medicine, Baltimore
Kathryn Edwards - Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee
C Buddy Creech - Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee
Sharon E Frey - Department of Internal Medicine, Saint Louis University, Missouri
Tamara P Blevins - Department of Internal Medicine, Saint Louis University, Missouri
Rachelle Salomon - Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Robert B Belshe - Department of Internal Medicine, Saint Louis University, Missouri
Resource Type: Journal article
Publication Details: The Journal of infectious diseases, Vol.214(7), pp.1020-1029
DOI: 10.1093/infdis/jiw310
PMID: 27443611
PMCID: PMC5021235
ISSN: 0022-1899
eISSN: 1537-6613
Grant note: HHSN272200800002C / NIAID NIH HHS HHSN272200800001C / NIAID NIH HHS HHSN272200800001G / NIAID NIH HHS HHSN272200800003C / NIAID NIH HHS HHSN272200800006C / NIAID NIH HHS HHSN272200800007C / NIAID NIH HHS HHSN272200800008C / NIAID NIH HHS HHSN272200800001I / NIAID NIH HHS HHSN272200800001O / NIAID NIH HHS
Language: English
Date published: 10/01/2016
Academic Unit: Infectious Diseases; Medicine Administration; Internal Medicine
Record Identifier: 9984094335102771

Metrics

22 Record Views

7 Times Cited - Web of Science

See more details